Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IAPT

- PMLiVE

Doctors worried NHS is unprepared for coronavirus as government unveils action plan

Concerns raised as government reveals key planning document

- PMLiVE

Celgene’s Revlimid scores NICE approval in follicular lymphoma

New ‘chemotherapy-free’ treatment for patients with limited options

- PMLiVE

NHS reliance on ‘short-term measures’ has made it financially unstable, auditors report

Quick fixes are draining funding for long-term investment

- PMLiVE

NICE plans to widen the net for data it uses in guidance

Plans to include electronic health records and real-world evidence

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

- PMLiVE

NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi

Initial guidance says drug is too costly but encourages further data

- PMLiVE

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

Cost-effectiveness watchdog issues a round of draft and final guidance

- PMLiVE

Novartis links up with NHS for speedy access to cholesterol drug inclisiran

Collaboration will see drug offered to patients across the UK via clinical study

- PMLiVE

Health research crisis in the NHS is putting patient care at risk

New report highlights importance of research in the health service

- PMLiVE

NICE rejects Akcea’s rare inherited disorder drug Waylivra

Draft guidance deems drug too costly for NHS use

- PMLiVE

NICE knocks back Roche’s Tecentriq for small cell lung cancer

Insufficient evidence to approve use in SCLC on the NHS

- PMLiVE

NHS plans to cut certain routine tests as part of cost-saving efforts

Under proposed plans tests will only be used in exceptional situations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links